|
123
|
313
|
5seuA |
Crystal structure of human phosphodiesterase 10 in complex with 2-[2-(2-methyl-5-pyrrolidin-1-yl-1,2,4-triazol-3-yl)ethyl]-6-(trifluoromethyl)-[1,2,4]triazolo[1,5-a]pyridine |
|
126
|
314
|
5sjxA |
Crystal structure of human phosphodiesterase 10 in complex with 2-[[4-(1-methyl-4-pyridin-4-ylpyrazol-3-yl)phenoxy]methyl]quinoline |
|
125
|
313
|
5sfrA |
Crystal structure of human phosphodiesterase 10 in complex with 4-n-ethyl-3-n-[2-[3-(2-fluoroethoxy)phenyl]imidazo[1,2-a]pyrimidin-7-yl]-4-n,2-dimethylpyrazole-3,4-dicarboxamide |
|
126
|
313
|
5sfwA |
Crystal structure of human phosphodiesterase 10 in complex with 5-ethyl-8-methyl-2-[2-(2-methyl-5-pyrrolidin-1-yl-1,2,4-triazol-3-yl)ethyl]-[1,2,4]triazolo[1,5-c]pyrimidine |
|
127
|
313
|
5shgA |
Crystal structure of human phosphodiesterase 10 in complex with 3-(2-chlorophenyl)-12-methoxy-5-methyl-2,4,8,13-tetrazatricyclo[7.4.0.02,6]trideca-1(9),3,5,7,10,12-hexaen-7-amine |
|
127
|
313
|
5si5A |
Crystal structure of human phosphodiesterase 10 in complex with n-(12-methoxy-5-methyl-3-propyl-2,4,8,13-tetrazatricyclo[7.4.0.02,6]trideca-1(13),3,5,7,9,11-hexaen-7-yl)methanesulfonamide |
|
128
|
313
|
5sg3A |
Crystal structure of human phosphodiesterase 10 in complex with n-[(e)-(4-bromo-3,5-dimethoxyphenyl)methylideneamino]-2-ethoxy-2-(4-morpholin-4-ylphenyl)acetamide |
|
122
|
313
|
5sjjA |
Crystal structure of human phosphodiesterase 10 in complex with 4-n-ethyl-5-[3-(trifluoromethyl)phenyl]-7h-pyrrolo[2,3-d]pyrimidine-2,4-diamine |
|
127
|
313
|
5skcA |
Crystal structure of human phosphodiesterase 10 in complex with 6-methyl-n-(1-propan-2-ylpyrazol-3-yl)-3-(pyrimidin-5-ylamino)pyridine-2-carboxamide |
|
124
|
312
|
5sidA |
Crystal structure of human phosphodiesterase 10 in complex with 5-chloro-2-[2-(6,8-dichloro-5-methyl-[1,2,4]triazolo[1,5-a]pyridin-2-yl)ethyl]-1,3-benzothiazole |
|
126
|
313
|
5seqA |
Crystal structure of human phosphodiesterase 10 in complex with 5,6,8-trimethyl-2-[2-(2-methyl-5-pyrrolidin-1-yl-1,2,4-triazol-3-yl)ethyl]-[1,2,4]triazolo[1,5-a]pyrazine |
|
128
|
315
|
5se1A |
Crystal structure of human phosphodiesterase 10 in complex with 6-cyclopropyl-n-[3-(dimethylcarbamoyl)-1-methylpyrazol-4-yl]-3-(pyrimidin-5-ylamino)pyridine-2-carboxamide |
|
114
|
434
|
7eg1A |
Cryo-em structure of dnmdp-induced pde3a-slfn12 complex |
|
112
|
434
|
7eg4A |
Cryo-em structure of nauclefine-induced pde3a-slfn12 complex |
|
108
|
434
|
7eg0A |
Cryo-em structure of anagrelide-induced pde3a-slfn12 complex |
|
134
|
432
|
7lrdB |
Cryo-em of the slfn12-pde3a complex: consensus subset model |
|
134
|
432
|
7lrcB |
Cryo-em of the slfn12-pde3a complex: pde3a body refinement |
|
140
|
376
|
7l27A |
Crystal structure of the catalytic domain of human pde3a |
|
147
|
377
|
7kweA |
Crystal structure of the catalytic domain of human pde3a bound to dnmdp |
|
141
|
377
|
7l28A |
Crystal structure of the catalytic domain of human pde3a bound to trequinsin |
|
142
|
377
|
7l29A |
Crystal structure of the catalytic domain of human pde3a bound to amp |
|
137
|
339
|
6zqzA |
[1,2,4]triazolo[1,5-a]pyrimidine phosphodiesterase 2 inhibitors |
|
123
|
312
|
7bpiA |
The crystal structue of pde10a complexed with 14 |
|
127
|
326
|
6zndA |
[1,2,4]triazolo[1,5-a]pyrimidine phosphodiesterase 2 inhibitors |
|
142
|
354
|
6blfA |
Pde2 complexed with 2-[6-fluoro-8-methylsulfonyl-9-[(1r)-1-[4-(trifluoromethyl)phenyl]ethyl]-1,2,3,4-tetrahydrocarbazol-1-yl]acetic acid |
|
134
|
322
|
6mscA |
Novel, potent, selective and brain penetrant phosphodiesterase 10a inhibitors |
|
130
|
328
|
6msaA |
Novel, potent, selective and brain penetrant phosphodiesterase 10a inhibitors |
|
120
|
323
|
5znlA |
Crystal structure of pde10a catalytic domain complexed with lhb-6 |
|
113
|
324
|
6ijiA |
Crystal structure of pde10 in complex with inhibitor 2b |
|
122
|
322
|
6ijhA |
Crystal structure of pde10 in complex with inhibitor af-399/14387019 |
|
115
|
312
|
5k9rA |
Pde10a with imidazopyrazine inhibitor |
|
130
|
313
|
5i2rA |
Human pde10a in complex with 3-(2-phenylpyrazol-3-yl)-1-[3-(trifluoromethoxy)phenyl]pyridazin-4-one |
|
140
|
342
|
6ezfA |
Pde2 in complex with molecule 5 |
|
135
|
352
|
6cycA |
Pde2 in complex with compound 5 |
|
132
|
352
|
6cydA |
Pde2 in complex with compound 7 |
|
134
|
352
|
6cybA |
Pde2 in complex with compound 7 |
|
140
|
339
|
6c7fA |
Crystal structure of human phosphodiesterase 2a with 1-(2-chloro-5-isobutoxy-phenyl)-n,4-dimethyl-[1,2,4]triazolo[4,3-a]quinoxaline-8-carboxamide |
|
135
|
342
|
6c7dA |
Crystal structure of human phosphodiesterase 2a with n-(1-adamantyl)-1-(2-chlorophenyl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline-8-carboxamide |
|
137
|
342
|
6c7eA |
Crystal structure of human phosphodiesterase 2a with 1-(2-chlorophenyl)-n,4-dimethyl-[1,2,4]triazolo[4,3-a]quinoxaline-8-carboxamide |
|
133
|
341
|
6c7gA |
Crystal structure of human phosphodiesterase 2a with n-(1-adamantyl)-1-(2-chloro-5-isobutoxy-phenyl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline-8-carboxamide |
|
136
|
342
|
6c7jA |
Crystal structure of human phosphodiesterase 2a with 1-(5-tert-butoxy-2-chloro-phenyl)-n-isobutyl-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline-8-carboxamide |
|
136
|
342
|
6c7iA |
Crystal structure of human phosphodiesterase 2a with 1-(2-chloro-5-methoxy-phenyl)-n-isobutyl-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline-8-carboxamide |
|
134
|
352
|
6b97A |
Crystal structure of pde2 in complex with complex 9 |
|
136
|
352
|
6b96A |
Crystal structure of pde2 in complex with compound 16 |
|
130
|
353
|
6b98A |
Pde2 in complex with compound 1 |
|
132
|
340
|
5xkmA |
Crystal structure of human phosphodiesterase 2a in complex with 6-methyl-n-(1-(4-(trifluoromethoxy)phenyl)propyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide |
|
121
|
322
|
5xujA |
Crystal structure of pde10a in complex with 7-(4-chlorophenyl)-2-methylpyrazolo[1,5-a]pyrimidine |
|
125
|
322
|
5xuiA |
Crystal structure of pde10a in complex with 2-methyl-5-[2-([1,2,4]triazolo[1,5-a]pyrimidin-2-yl)et hyl]pyrazolo[1,5-a]pyrimidin-7-ol |
|
135
|
353
|
5w6eA |
Pde1b complexed with compound 3s |
|
130
|
338
|
5u7iA |
Pde2 catalytic domain complexed with inhibitors |
